|
|
.
See Category: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
See Header: Hemorrhagic disorder due to intrns circ anticoag,antib,inhib
ICD-10 (CM) Code and Descriptor
|
D68.311 |
Acquired hemophilia
|
D68311 utilizaton on OPPS claims.*
Primary
ICD10 Code |
ICD10
Position 2 |
ICD10
Position 3 |
ICD10
Position 4 |
ICD10
Position 5 |
ICD10
Position 6 |
ICD10
Position 7 |
ICD10
Position 8 |
ICD10
Position 9 |
ICD10
Position 10 |
| 54.57%
|
18.35%
|
8.44%
|
5.49%
|
3.66%
|
2.54%
|
3.72%
|
1.12%
|
0.24%
|
0.41%
|
* Medicare Part A utilization data is derived from the 100% 2023 Outpatient (Fee-for-Service) Standard Analytical File.
Commonly Associated Procedure Codes for D68.311*:
| CPT |
Description |
Number of Claims |
Sum Performed |
|
36415
|
COLL VENOUS BLD VENIPUNCTURE |
430
|
436
|
|
85025
|
COMPLETE CBC W/AUTO DIFF WBC |
404
|
404
|
|
85240
|
CLOT FACTOR VIII AHG 1 STAGE |
401
|
467
|
|
85730
|
THROMBOPLASTIN TIME PARTIAL |
331
|
358
|
|
80053
|
COMPREHEN METABOLIC PANEL |
217
|
217
|
|
G0463
|
HOSPITAL OUTPT CLINIC VISIT |
193
|
193
|
|
96365
|
THER/PROPH/DIAG IV INF INIT |
181
|
183
|
|
85335
|
FACTOR INHIBITOR TEST |
180
|
190
|
|
J7198
|
ANTI-INHIBITOR |
167
|
719,738
|
|
85610
|
PROTHROMBIN TIME |
161
|
164
|
|
85027
|
COMPLETE CBC AUTOMATED |
70
|
70
|
|
J9312
|
INJ., RITUXIMAB, 10 MG |
63
|
2,372
|
|
96413
|
CHEMO IV INFUSION 1 HR |
62
|
62
|
|
J7189
|
FACTOR VIIA RECOMB NOVOSEVEN |
60
|
562,000
|
|
85390
|
FIBRINOLYSINS SCREEN I&R |
55
|
55
|
|
J7170
|
INJ., EMICIZUMAB-KXWH 0.5 MG |
54
|
13,785
|
|
96415
|
CHEMO IV INFUSION ADDL HR |
51
|
92
|
|
85732
|
THROMBOPLASTIN TIME PARTIAL |
46
|
63
|
|
85130
|
CHROMOGENIC SUBSTRATE ASSAY |
45
|
45
|
|
82728
|
ASSAY OF FERRITIN |
43
|
43
|
* Derived from 100% 2021 Outpatient (Fee-for-Service) Standard Analytical File.
D68.311 related to the following DRG Codes:
813
|
